Asset Details
Do you wish to reserve the book?
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Do you wish to request the book?
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
2020
Overview
In a 24-week trial involving patients with rheumatoid arthritis that was refractory to biologic agents, the JAK1 inhibitor upadacitinib was superior to the T-cell costimulation modulator abatacept in reducing disease activity as assessed by a composite measure of joint changes and C-reactive protein level.
Publisher
Massachusetts Medical Society
Subject
/ Antirheumatic Agents - adverse effects
/ Antirheumatic Agents - therapeutic use
/ Arthritis, Rheumatoid - blood
/ Arthritis, Rheumatoid - drug therapy
/ C-Reactive Protein - analysis
/ Female
/ Heterocyclic Compounds, 3-Ring - adverse effects
/ Heterocyclic Compounds, 3-Ring - therapeutic use
/ Humans
/ Inducible T-Cell Co-Stimulator Protein - antagonists & inhibitors
/ Janus Kinase Inhibitors - adverse effects
/ Janus Kinase Inhibitors - therapeutic use
/ Kinases
/ Male
/ Patients
